Previously untreated adult (w/ normal renal function) 400 mg/m2 by IV infusion over 15 min to 1 hr. Doses should not be given more frequently than every 4 wk. Renal failure CrCl 41-56 mL/min Initially 250 mg/m2. CrCl 16-40 mL/min Initially 200 mg/m2.
Hypersensitivity to carboplatin or other platinum containing compd. Severe myelosuppression; bleeding tumours; pre-existing severe renal impairment (CrCl ≤20 mL/min). Breast-feeding.
Patients w/ abnormal kidney function or receiving concomitant therapy w/ other drugs w/ nephrotoxic potential. Assess carefully renal function parameters before & during therapy. Infusion courses should not be repeated more frequently than mthly under normal circumstances. Monitor peripheral blood counts frequently. Combination therapy w/ other myelosuppressive compds. Supportive transfusional therapy may be required in patients who suffer severe myelosuppression. May cause nausea & vomiting. Renal & hepatic function impairment. Increased incidence of allergic reactions w/ previous exposure to platinum therapy. Perform neurological evaluation & assessment of hearing on a regular basis especially when receiving high dose. Do not use Al containing equipment during prep & administration. Women of childbearing potential & pregnancy. Childn.
Increased risk of induced nephrotoxicity & ototoxicity w/ aminoglycosides (eg, amikacin, gentamycin, tobramycin). May decrease serum level of phenytoin. May decrease serum level of phenytoin. May increase anticoagulant effect of warfarin. May potentiate renal effects of nephrotoxic drugs. May cause more severe bone marrow depression w/ bone marrow suppressing drugs or w/ radiotherapy.
Sign Out
